Genuine Biotech Overview
- Year Founded
-
2012
- Status
-
IPO Registration
- Employees
-
220
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
6
Genuine Biotech General Information
Description
Developer of antiviral and antitumor drugs intended to serve cancer and HIV patients. The company develops and produces varieties of drugs such as anticancer drugs, antiviral drugs, diabetes-related disease treatment drugs, and cardiovascular and cerebrovascular and aging-related diseases, providing cancer and HIV patients with oral medication.
Contact Information
Website
www.genuine-bio.comCorporate Office
- No. 1 Building, No. 10 Courtyard, Middle Section of Fuxing Road
- Xincheng District
- Pingdingshan, Henan
- China
Corporate Office
- No. 1 Building, No. 10 Courtyard, Middle Section of Fuxing Road
- Xincheng District
- Pingdingshan, Henan
- China
Genuine Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 18-Feb-2025 | Announced | Generating Revenue | |||
| 4. IPO | 05-Aug-2022 | Cancelled | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 12-Apr-2022 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 22-Jan-2022 | $23.1M | Completed | Generating Revenue | ||
| 1. Later Stage VC (Series A) | 22-Feb-2021 | $23.1M | $23.1M | Completed | Generating Revenue |
Genuine Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genuine Biotech Patents
Genuine Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223725-A1 | Novel pharmaceutical use of azvudine or pharmaceutically acceptable salt thereof or combination thereof with hiv inhibitor | Pending | 23-Apr-2025 | ||
| WO-2026201141-A1 | Pharmaceutical composition, preparation thereof and use thereof | Pending | 28-Mar-2025 | ||
| WO-2026119167-A1 | Pharmaceutical use of azvudine drug | Pending | 03-Dec-2024 | ||
| WO-2026082191-A1 | Pharmaceutical use of azvudine drug | Pending | 18-Oct-2024 | ||
| EP-4685153-A1 | Broad-spectrum viral membrane fusion inhibitor, and preparation method therefor and use thereof | Pending | 20-Mar-2023 | A61P31/18 |
Genuine Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genuine Biotech Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABC Capital | Venture Capital | Minority | ||
| Desano (Shanghai) | PE-Backed Company | Minority | ||
| GoFintech Innovation | Asset Manager | Minority | ||
| Yingke Capital | Venture Capital | Minority | ||
| Goldlark Investment Consultation | Mutual Fund | Minority |
Genuine Biotech FAQs
-
When was Genuine Biotech founded?
Genuine Biotech was founded in 2012.
-
Where is Genuine Biotech headquartered?
Genuine Biotech is headquartered in Pingdingshan, China.
-
What is the size of Genuine Biotech?
Genuine Biotech has 220 total employees.
-
What industry is Genuine Biotech in?
Genuine Biotech’s primary industry is Pharmaceuticals.
-
Is Genuine Biotech a private or public company?
Genuine Biotech is a Private company.
-
What is Genuine Biotech’s current revenue?
The current revenue for Genuine Biotech is .
-
How much funding has Genuine Biotech raised over time?
Genuine Biotech has raised $112M.
-
Who are Genuine Biotech’s investors?
ABC Capital, Desano (Shanghai), GoFintech Innovation, Yingke Capital, and Goldlark Investment Consultation are 5 of 6 investors who have invested in Genuine Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
